Skip to main content
    B

    Boston Scientific Corp (BSX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $43.70
    -0.64 (-1.44%)

    Market Cap: $64.27B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Boston Scientific Corp (BSX) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Boston Scientific (BSX) trades at 13.7x trailing earnings and 3.0x sales. Its P/E of 13.7x is below its 5-year median of 28.4x. Its forward P/E is 14.3x. The median P/E across 10 similar companies is 20.9x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 4.2% lower over the next year. Its free cash flow yield is 5.3%.

    MultipleValue
    P/E (trailing)13.7x
    Forward P/E14.3x
    Price to sales3.0x
    Price to book2.5x
    EV/EBITDA13.6x
    Price to FCF19.0x
    EV/FCF22.4x
    PEG0.8
    FCF yield5.3%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 49.4% below 27.1x, its P/S is 44.4% below 5.4x and its P/B is 46.8% below 4.7x.

    MultipleCurrent5-year median10-year median
    P/E13.7x28.4x27.1x
    P/S3.0x5.7x5.4x
    P/B2.5x4.2x4.7x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 19.3x in 2016 to 37.4x in 2020.

    Year endPriceP/EP/SP/B
    2025$95.3531.3x7.0x5.9x
    2024$89.3235.6x7.9x6.1x
    2023$57.8128.2x5.9x4.4x
    2022$46.2727.1x5.2x3.8x
    2021$42.4826.1x5.1x3.7x
    2020$35.9537.4x5.2x3.4x
    2019$45.2228.4x5.9x4.6x
    2018$35.3423.9x5.0x5.7x
    2017$24.7919.7x3.8x4.9x
    2016$21.6319.3x3.5x4.4x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About BSX

    What is BSX's forward P/E ratio?

    Boston Scientific has a forward P/E ratio of 14.3x.

    Is BSX stock overvalued?

    GNG's valuation label for BSX is Undervalued. Its P/E of 13.7x compares with a median of 20.9x across 10 similar companies.

    What is BSX's price to sales ratio?

    Boston Scientific has a price to sales ratio of 3.0x.

    What is Boston Scientific's average P/E ratio over 5 years?

    Boston Scientific's median P/E over the last 5 years is 28.4x, from 60 month-end values through Oct 2026.

    What is BSX's PEG ratio?

    Boston Scientific has a PEG ratio of 0.8.